Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Set Alert for Articles By Jessica Merrill

Latest From Jessica Merrill

BMS Outlines Clinical Trial Disruptions, Reassures Supply Chain Secure

The company is the latest big pharma to announce clinical trial delays due to the COVID-19 pandemic and has postponed an R&D day, but it also delivered the message that supply and commercial operations appear on track.

Clinical Trials Coronavirus COVID-19

Biogen Spinraza Treatment Delays Show COVID-19 Is Already Impacting Hospital Treatments

Biogen confirmed that some patients treated with Spinraza are temporarily having their dosing postponed as hospital systems brace for COVID-19, potentially a broader issue for the industry. 

Coronavirus COVID-19 Business Strategies

Sage Plans New Trials And Approval Timeline For Zuranolone

Sage will initiate three new trials to support FDA approval of the drug for post-partum depression and major depressive disorder, with data anticipated in 2021.

Neurology Clinical Trials

Bad For Pharma: Sales Reps And Patients Are Staying Home

Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.

Advertising, Marketing & Sales Coronavirus COVID-19

Sanofi And Regeneron Initiate 400-Patient Coronavirus Trial With Kevzara

The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials. 

Clinical Trials Coronavirus COVID-19

For Drugs That Increase Risk Of Infection, More Questions Than Answers In The Coronavirus Era

Autoimmune disease drugs ranging from Humira to Cosentyx to Tremfya to Xeljanz carry warnings about increased risk of infections. This raises new questions in the novel coronavirus outbreak.

Coronavirus COVID-19 Immune Disorders
See All
UsernamePublicRestriction

Register